A strong track record in drug development services. A continuous integration of innovative technologies and capacities extension.
Years of experience
ClaireDUBOIS BERGERGeneral Secretary Business School (ESCP)
Claire has a senior experience in supporting groups growth in integrating new activities and business acquisitions. Her background and skills cover controlling & accounting, project financing, IT, legal and management of support services. Claire will focus on IT including the ERP and integration of subsidiaries, structuring the core system while preserving agility and identity of each entity.
FrédéricGAUSSENSVP Business Development & Strategy Master Degree of Finance
Frédéric has 10 years+ experience within Life Science outsourcing industry through several managerial positions in Finance, Marketing, Strategy and Business Development across various global companies. Frédéric will focus on key strategic initiatives to support Amatsigroup international expansion: build up and M&A, alliances, partnerships and corporate development, and will bolster the company brand awareness.
YvesGONNISSENManaging Director PhD, Biochem.Eng
Yves has 15 years of experience in pharmaceutical product development. He holds a Master’s degree in Biochemical Engineering. He obtained his PhD at Ghent University in Belgium where he pursued his research interests in the fields of pharmaceutical technology and pharmaceutical drug product development. In 2002 he started his professional career at Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). In 2007 he founded SEPS Pharma specialized in drug product development. In 2015, Amatsigroup acquired his company. Ever since, he has managed Amatsigroup services in formulation development & manufacturing focusing on innovative technologies especially for bioavailiability enhancement or oral controlled release.
Jean-FrançoisCORDOLIANISite Manager Pharmacist
Jean-François joined Amatsigroup as Head of Pharmaceutical Development in 2016. He has a senior expertise of 30 years in pharmaceutical development (Pierre Fabre, BMS &UPSA) on innovative drugs & life cycle management. His key assets: A client-oriented approach, a broad experience in pharmaceutical development strategy and a strong industrial background, including intellectual property. He is specialized also in dermatology and skin care products. Jean-François is in charge of leading the formulation team on French sites & managing the analytical site of St Augustin.
FranckPAVANSterile Manufacturing Sites Director Biochem.Eng
Franck has 20 years background in manufacturing sterile products. He is an expert in aseptic manufacturing for high potent, conventional, vaccine products. Highly skilled in isolators, this expertise has been spread worldwide through multiple speaking interventions in worldwide congresses. With more than 16 years experience at Pierre Fabre laboratories on liquid and freeze dried drug products, he managed multiple process transfers for clinical and commercial products manufacturing at a global level. In 2016, he joined Amatsigroup to lead the aseptic manufacturing activities of the group.
Amatsigroup achieved the process transfer of our injectable drug from a major industrial manufacturer and successfully managed the critical step of lyophilization. Amatsigroup has demonstrated its high adaptability to the manufacture of small batches suitable for the orphan drug market. To accommodate our expansion on the Japanese market, Amatsigroup’s team was very reactive and involved and got the Japanese PDMA accreditation within the expected timeframe.
Christophe Pasik, CEO
Keocyt SAS, A Riemser Group company
Amatsigroup is a very expertise based and science driven company focussing on the priorities of the sponsor/client. Over the last five to six years they evolved to a well-balanced group of highly experienced, flexible and self-driving teams, invested in premises and equipment allowing them to cope with standard and specialty project requirements in the formulation and analytical domain for pre-clinical and clinical needs.
John Oliver, Head CMC Development
Major biotech company